Contact Us

Watch hVIVO’s July 2024 Capital Markets Day here

Result Centre

Who Are We?

We are a full-service early phase Contract Research Organisation (CRO) and the global leader in human challenge trials. The Company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world’s ten largest biopharma companies.

Results Archive

2025
2024
2023
2022
Archive

Performance in H1 25

Yamin 'Mo' Khan

CEO at hVIVO

"The broader CRO industry has been impacted by macroeconomic and sector-specific headwinds, and hVIVO is no exception. However, we are greatly encouraged by the early success of our diversification strategy and by the strength of our pipeline, with the aggregate value of customer proposals submitted in H1 2025 exceeding FY24. Looking ahead we are focused on finalising the integration of CRS and Cryostore into the Group, realising further synergies presented by these bolt-ons, converting our pipeline into revenue, and positioning the business to return to sustainable growth in 2026 and beyond."

Latest Investor Presentation

23 Sep 2025
HVIVO PLC - Interim Results
Example Stat
0
Example Stat
0
Example Stat
0
Example Stat
0

H1 25 Revenue

£0M

H1 25 EBITDA Margin

0%

Cash 30 June 2025

£0M

FY24 Guidance

£0M
Mission:
Delivering today’s healthcare by empowering tomorrow’s innovation.
Vision:
To transform global healthcare by revolutionising the drug development process through scientific ingenuity.

Quick Links

Contact our Investor Relations team.

IR@hVIVO.com

Stay connected

Sign up to our emails and follow us on social media to keep up to date with hVIVO.

By clicking Sign Up you're confirming that you agree with our Privacy Policy.
chevron-downarrow-up